Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Acromegaly | Research

Recurrent acromegaly: a systematic review on therapeutic approaches

Authors: Seyed Farzad Maroufi, Mohammadmahdi Sabahi, Seyed Sahab Aarabi, Mohammad Samadian, Rocco Dabecco, Badih Adada, Karla M. Arce, Hamid Borghei-Razavi

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background and objective

Management of recurrent acromegaly is challenging for both neurosurgeons and endocrinologists. Several treatment options including repeat surgery, medical therapy, and radiation are offered for such patients. The efficacy of these modalities for the treatment of recurrence has not been studied previously in the literature. In this study, we aim to systematically review the existing cases of recurrence and come to a conclusion regarding the appropriate treatment in such cases.

Method

A systematic review was performed through PubMed, Scopus, Web of Science, and Cochrane database to identify studies reporting the treatment outcome of recurrent acromegaly patients. Using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, the included studies were reviewed for primary and secondary treatment, complications, and outcomes of the secondary treatment.

Results

The systematic review retrieved 23 records with 95 cases of recurrent acromegaly. The mean time of recurrence was 4.16 years after the initial treatment. The most common primary treatment was surgery followed by radiotherapy. The remission rate was significantly higher in medical and radiotherapy compared to surgical treatment.

Conclusion

In cases of recurrent acromegaly, the patient may benefit more from radiotherapy and medical therapy compared to surgery. As the quality of evidence is low on this matter feature studies specifically designed for recurrent patients are needed.
Literature
1.
Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9.PubMedCrossRef
2.
Hage M, Kamenický P, Chanson P. Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology. 2019;108(3):244–55.PubMedCrossRef
3.
Del Porto LA, Liubinas SV, Kaye AH. Treatment of persistent and recurrent acromegaly. J Clin Neurosci. 2011;18(2):181–90.PubMedCrossRef
4.
5.
Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK, et al. Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab. 2020;105(3):e532–43.PubMedCrossRef
6.
Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89(2):495–500.PubMedCrossRef
7.
Buchfelder M, Brockmeier S, Fahlbusch R, Honegger J, Pichl J, Manzl M. Recurrence following transsphenoidal surgery for acromegaly. Hormone Res Paediatr. 1991;35(3–4):113–8.CrossRef
8.
Besser G, Burman P, Daly A. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153(2):187–93.PubMedCrossRef
9.
Krieger MD, Couldwell WT, Weiss MH. Assessment of long-term remission of acromegaly following surgery. J Neurosurg. 2003;98(4):719–24.PubMedCrossRef
10.
Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100(1):122–31.PubMedCrossRef
11.
Koulouri O, Steuwe A, Gillett D, Hoole AC, Powlson AS, Donnelly NA, et al. A role for 11C-methionine PET imaging in ACTH-dependent Cushing’s syndrome. Eur J Endocrinol. 2015;173(4):M107–20.PubMedCrossRef
12.
Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85(7):2476–82.PubMedCrossRef
13.
Roug S, Rasmussen Å, Juhler M, Kosteljanetz M, Poulsgaard L, Heebøll H, et al. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Eur J Endocrinol. 2010;162(4):685.PubMedCrossRef
14.
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg. 1998;88(6):1002–8.PubMedCrossRef
15.
Gatto F, Feelders RA, Van Der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66–71.PubMedCrossRef
16.
Katznelson L. Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab. 2010;95(9):4114–23.PubMedCrossRef
17.
Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR. Pharmacological management of acromegaly: a current perspective. Neurosurg Focus. 2010;29(4):E14.PubMedCrossRef
18.
Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary. 2017;20(1):129–35.PubMedCrossRef
19.
Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 1988;68(6):854–67.PubMedCrossRef
20.
Salinger DJ, Brady LW, Miyamoto CT. Radiation therapy in the treatment of pituitary adenomas. Am J Clin Oncol. 1992;15(6):467–73.PubMedCrossRef
21.
Long H, Beauregard H, Somma M, Comtois R, Serri O, Hardy J. Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg. 1996;85(2):239–47.PubMedCrossRef
22.
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83(10):3411–8.PubMedCrossRef
23.
Freda PU, Wardlaw SL, Post K. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998;89(3):353–8.PubMedCrossRef
24.
Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(10):3419–26.PubMed
25.
Biermasz NR, Van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab. 2000;85(12):4596–602.PubMedCrossRef
26.
Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg. 2002;97(3):525–30.PubMedCrossRef
27.
Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM, Ramirez A, Ortega S, Sabatel G, et al. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol. 2005;78(926):110–5.PubMedCrossRef
28.
Landolt AM, Lomax N, Scheib SG, Girard J. Gamma Knife surgery after fractionated radiotherapy for acromegaly. J Neurosurg. 2006;105:31–6.PubMedCrossRef
29.
Petit JH, Biller BMK, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007;13(7):726–34.PubMedCrossRef
30.
Jagannathan J, Sheehan JP, Pouratian N, Laws ER Jr, Steiner L, Vance ML. Gamma knife radiosurgery for acromegaly: Outcomes after failed transsphenoidal surgery. Neurosurgery. 2008;62(6):1262–9.PubMed
31.
Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 2008;93(7):2546–52.PubMedCrossRef
32.
Yamada S, Fukuhara N, Oyama K, Takeshita A, Takeuchi Y. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly. Neurosurgery. 2010;67(4):949–56.PubMedCrossRef
33.
Albarel F, Castinetti F, Morange I, Conte-Devolx B, Gaudart J, Dufour H, et al. Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol. 2013;78(2):263–70.CrossRef
34.
Van Rompaey K, Unuane D, Moens M, Duerinck J, Poppe K, Velkeniers B, et al. Long-term follow-up results of multimodal treatment with initial surgical approach for acromegaly in a single center. Acta Neurol Belg. 2013;113(1):49–54.PubMedCrossRef
35.
Sankhla SK, Jayashankar N, Khan GM. Surgical management of selected pituitary macroadenomas using extended endoscopic endonasal transsphenoidal approach: early experience. Neurol India. 2013;61(2):122–30.PubMedCrossRef
36.
Shirvani M, Motiei-Langroudi R. Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients. World Neurosurg. 2014;81(1):125–30.PubMedCrossRef
37.
Sun H, Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. J Neurol Surg Part B, Skull Base. 2014;75(1):47–52.CrossRef
38.
Sinha S, Sarkari A, Mahapatra AK, Sharma BS. Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients. Childs Nerv Syst. 2014;30(8):1405–11.PubMedCrossRef
39.
Paluzzi A, Fernandez-Miranda JC, Stefko ST, Challinor S, Snyderman CH, Gardner PA. Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary. 2014;17(4):307–19.PubMedCrossRef
40.
Losa M, Spatola G, Albano L, Gandolfi A, Del Vecchio A, Bolognesi A, et al. Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas. Endocrine. 2017;56(3):595–602.PubMedCrossRef
41.
Ismail M, Ragab OAAAM, Salama MM, Ayoub BM, Elmahdy W. Transcranial versus endoscopic transsphenoidal approaches in management of recurrent giant pituitary adenomas. Open Access Macedonian J Med Sci. 2020;8(1):273–80.CrossRef
42.
Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972–8.PubMedCrossRef
43.
Reid TJ, Jin Z, Shen W, Reyes-Vidal CM, Fernandez JC, Bruce JN, et al. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary. 2015;18(6):808–19.PubMedPubMedCentralCrossRef
44.
Shen M, Chen Z, Shou X, He W, Qiao N, Ma Z, et al. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly. J Neuroendocrinol. 2021;33(5):e12958.PubMedCrossRef
45.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51.PubMedCrossRef
46.
Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JA, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–61.PubMedPubMedCentralCrossRef
47.
Giustina A, Barkan A, Beckers A, Biermasz N, Biller BM, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020;105(4):e937–46.CrossRef
48.
Feelders R, Bidlingmaier M, Strasburger C, Janssen J, Uitterlinden P, Hofland L, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab. 2005;90(12):6480–9.PubMedCrossRef
49.
Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab. 2005;90(3):1377–82.PubMedCrossRef
50.
Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A. Adequacy of current postglucose GH nadir limit (< 1 µg/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol. 2007;66(4):538–42.CrossRef
51.
Freda PU, Bruce JN, Reyes-Vidal C, Singh S, DeLeon Y, Jin Z, et al. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary. 2021;24(2):170–83.PubMedCrossRef
52.
Biermasz NR, Smit JW, Van Dulken H, Roelfsema F. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clin Endocrinol. 2002;56(3):313–9.CrossRef
53.
Minniti G, Jaffrain-Rea M, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer. 2003;10(4):611–9.PubMedCrossRef
54.
Kreutzer J, Vance M, Lopes M, Laws E Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072–7.PubMedCrossRef
55.
Gheorghiu ML. Updates in outcomes of stereotactic radiation therapy in acromegaly. Pituitary. 2017;20(1):154–68.PubMedCrossRef
56.
Castinetti F, Brue T. Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat? Discov Med. 2010;10(51):107–11.PubMed
57.
Cohen-Inbar O, Ramesh A, Xu Z, Vance ML, Schlesinger D, Sheehan JP. Gamma knife radiosurgery in patients with persistent acromegaly or Cushing’s disease: long-term risk of hypopituitarism. Clin Endocrinol. 2016;84(4):524–31.CrossRef
58.
Wilson P, De-Loyde K, Williams J, Smee R. Acromegaly: a single centre’s experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator. J Clin Neurosci. 2013;20(11):1506–13.PubMedCrossRef
59.
Almeida JP, Ruiz-Treviño AS, Liang B, Omay SB, Shetty SR, Chen YN, et al. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature. J Neurosurg. 2018;129(2):404–16.PubMedCrossRef
60.
Jahangiri A, Wagner J, Han SW, Zygourakis CC, Han SJ, Tran MT, et al. Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations. J Neurosurg. 2014;121(1):67–74.PubMedCrossRef
61.
Bray DP, Mannam S, Rindler RS, Quillin JW, Oyesiku NM. Surgery for acromegaly: Indications and goals. Front Endocrinol. 2022;13:924589.CrossRef
62.
Higham CE, Chung T, Lawrance J, Drake WM, Trainer PJ. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol. 2009;71(1):86–91.CrossRef
63.
Coopmans EC, van der Lely AJ, Neggers SJCMM. Approach to the patient with treatment-resistant acromegaly. J Clin Endocrinol Metab. 2022;107(6):1759–66.PubMedPubMedCentralCrossRef
64.
Grasso LF, Auriemma RS, Pivonello R, Colao A. Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf. 2015;14(8):1213–26.PubMedCrossRef
65.
Öberg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016;23(12):R551–66.PubMedCrossRef
Metadata
Title
Recurrent acromegaly: a systematic review on therapeutic approaches
Authors
Seyed Farzad Maroufi
Mohammadmahdi Sabahi
Seyed Sahab Aarabi
Mohammad Samadian
Rocco Dabecco
Badih Adada
Karla M. Arce
Hamid Borghei-Razavi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01533-w

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue

Case Report

Follicular adenoma with a papillary architecture originating from an ectopic thyroid gland

Research

Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis: a retrospective propensity score matching analysis based on twenty year’s experience

Research

Effect of metformin on anti-mullerian hormone levels in women with polycystic ovarian syndrome: a systematic review and meta-regression analysis of randomized controlled trials with

Research

Effectiveness and safety of dermal matrix used for diabetic foot ulcer: a systematic review and meta-analysis of randomized controlled trials

Research

Plasma adiponectin/leptin ratio associates with subcutaneous abdominal and omental adipose tissue characteristics in women

Research

Socio-behavioral determinants of health-related quality of life among patients with type 2 diabetes: comparison between 2015 and 2018
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits